TY - JOUR
T1 - Compensatory evolution drives multidrug-resistant tuberculosis in central Asia
AU - Merker, Matthias
AU - Barbier, Maxime
AU - Cox, Helen
AU - Rasigade, Jean Philippe
AU - Feuerriegel, Silke
AU - Kohl, Thomas Andreas
AU - Diel, Roland
AU - Borrell, Sonia
AU - Gagneux, Sebastien
AU - Nikolayevskyy, Vladyslav
AU - Andres, Sönke
AU - Nübel, Ulrich
AU - Supply, Philip
AU - Wirth, Thierry
AU - Niemann, Stefan
N1 - Publisher Copyright:
© Merker et al.
PY - 2018/10
Y1 - 2018/10
N2 - Bacterial factors favoring the unprecedented multidrug-resistant tuberculosis (MDR-TB) epidemic in the former Soviet Union remain unclear. We utilized whole genome sequencing and Bayesian statistics to analyze the evolutionary history, temporal emergence of resistance and transmission networks of MDR Mycobacterium tuberculosis complex isolates from Karakalpakstan, Uzbekistan (2001–2006). One clade (termed Central Asian outbreak, CAO) dating back to 1974 (95% HPD 1969–1982) subsequently acquired resistance mediating mutations to eight anti-TB drugs. Introduction of standardized WHO-endorsed directly observed treatment, short-course in Karakalpakstan in 1998 likely selected for CAO-strains, comprising 75% of sampled MDR-TB isolates in 2005/2006. CAO-isolates were also identified in a published cohort from Russia (2008– 2010). Similarly, the presence of mutations supposed to compensate bacterial fitness deficits was associated with transmission success and higher drug resistance rates. The genetic make-up of these MDR-strains threatens the success of both empirical and standardized MDR-TB therapies, including the newly WHO-endorsed short MDR-TB regimen in Uzbekistan.
AB - Bacterial factors favoring the unprecedented multidrug-resistant tuberculosis (MDR-TB) epidemic in the former Soviet Union remain unclear. We utilized whole genome sequencing and Bayesian statistics to analyze the evolutionary history, temporal emergence of resistance and transmission networks of MDR Mycobacterium tuberculosis complex isolates from Karakalpakstan, Uzbekistan (2001–2006). One clade (termed Central Asian outbreak, CAO) dating back to 1974 (95% HPD 1969–1982) subsequently acquired resistance mediating mutations to eight anti-TB drugs. Introduction of standardized WHO-endorsed directly observed treatment, short-course in Karakalpakstan in 1998 likely selected for CAO-strains, comprising 75% of sampled MDR-TB isolates in 2005/2006. CAO-isolates were also identified in a published cohort from Russia (2008– 2010). Similarly, the presence of mutations supposed to compensate bacterial fitness deficits was associated with transmission success and higher drug resistance rates. The genetic make-up of these MDR-strains threatens the success of both empirical and standardized MDR-TB therapies, including the newly WHO-endorsed short MDR-TB regimen in Uzbekistan.
UR - http://www.scopus.com/inward/record.url?scp=85055617032&partnerID=8YFLogxK
U2 - 10.7554/eLife.38200
DO - 10.7554/eLife.38200
M3 - Article
C2 - 30373719
AN - SCOPUS:85055617032
SN - 2050-084X
VL - 7
JO - eLife
JF - eLife
M1 - e38200
ER -